ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Fc gamma RIIIA / CD16a

Fc gamma RIIIA / CD16a

概要

Name:Low affinity immunoglobulin gamma Fc region receptor III-A
Target Synonym:Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a),CD16a Antigen,IGFR3,FCG3,Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16),Fc Fragment Of IgG, Low Affinity III, Receptor For (CD16),Immunoglobulin G Fc Receptor III,Fc-Gamma Receptor III-2 (CD 16),Neutrophil-Specific Antigen NA,Fc-Gamma Receptor IIIb (CD16),Fc Gamma Receptor III-A,Fc Gamma Receptor IIIa,Fc-Gamma RIIIa,Fc-Gamma RIII,FCGRIII,FcRIIIa,FCR-10,FCRIII,IMD20,CD16,Low affinity immunoglobulin gamma Fc region receptor III-A,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
CD16a VHH - 01 PCC Solid Tumor Solid tumor,Hematoma

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
SCCHO-ATP059H Human CHO/Human CD16a (158V) Stable Cell Line (High Expression) Development Service
SCCHO-ATP059L Human CHO/Human CD16a (158V) Stable Cell Line (Low Expression) Development Service
SCCHO-ATP059M Human CHO/Human CD16a (158V) Stable Cell Line (Medium Expression) Development Service
CDA-H52H6 Human Human Fc gamma RIIIA / CD16a (F176, S197P) Protein, His Tag (MALS&SPR verified)
CDA-H52H6-structure
CDA-H52H6-sds
CDA-H52S1 Human Human Fc gamma RIIIA / CD16a (V176) Protein, HSA,His Tag (MALS & BLI verified)
CDA-H52S1-structure
CDA-H52S1-sds
CDA-H5290 Human Human Fc gamma RIIIA / CD16a (V176) Protein, SUMO,His Tag (MALS & BLI verified)
CDA-H5290-structure
CDA-H5290-sds
CDA-H82E9 Human Biotinylated Human Fc gamma RIIIA / CD16a (V176) Protein, Avitag™,His Tag (HPLC & SPR & BLI verified)
CDA-H82E9-structure
CDA-H82E9-sds
CDA-H82E9-hplc
CDA-H82E8 Human Biotinylated Human Fc gamma RIIIA / CD16a (F176) Protein, Avitag™,His Tag (SPR & BLI & MALS verified)
CDA-H82E8-structure
CDA-H82E8-sds
CD8-H52H4 Human Human Fc gamma RIIIA / CD16a (V176) Protein, His Tag (SPR & BLI & MALS verified)
CD8-H52H4-structure
CD8-H52H4-sds
CDA-H5220 Human Human Fc gamma RIIIA / CD16a (F176) Protein, His Tag (MALS & SPR verified)
CDA-H5220-structure
CDA-H5220-sds
ACRO Quality

生物活性データの一部

SCCHO-ATP059H-Cell-based assay
Fc gamma RIIIA / CD16a FACS

Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).

Protocol
SCCHO-ATP059L-Cell-based assay
Fc gamma RIIIA / CD16a FACS

Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).

Protocol
CDA-H52H6-SPR
Fc gamma RIIIA / CD16a SPR

Human CD16a (F176, S197P) Protein, His Tag (Cat. No. CDA-H52H6) captured on CM5 chip via anti-His antibody can bind Rituximab with an affinity constant of 0.414 μM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol
CDA-H82E9-SPR
Fc gamma RIIIA / CD16a SPR

Biotinylated Human CD16a (V176), Avitag,His Tag (SPR & BLI verified) (Cat. No. CDA-H82E9) captured on Biotin CAP- Series S Sensor Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 0.367μM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

カスタマーレビュー

Synonym Name

FCGR3A,CD16A,FCG3,FCGR3,IGFR3

Background

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed  natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Oxis Biotech, University Of Minnesota Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
AFM-13 AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Mycosis Fungoides Details
FT-538 FT-538 Phase 2 Clinical Fate Therapeutics Inc Solid tumours; Leukemia, Myeloid; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute Details
FT-516 FT-516 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details
FT-576 FT-576 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Bone Marrow Neoplasms; Multiple Myeloma Details
AFM-24 AFM-24 Phase 2 Clinical Affimed Solid tumours Details
SM-3321 SM-3321 Phase 1 Clinical Beijing StarMab BioMed Technology Ltd Leukemia, Myeloid, Acute Details
GMA-161 GMA-161 Phase 1 Clinical Sanofi, Macrogenics Inc Purpura, Thrombocytopenic, Idiopathic Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap